Press Releases

Oct 01, 2026

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

Sep 23, 2026

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Sep 22, 2026

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Sep 02, 2026

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 12, 2026

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Aug 05, 2026

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

Jun 17, 2026

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Jun 15, 2026

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

May 19, 2026

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 11, 2026

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights